Its valuation is considered undervalued,and institutional recognition is very high.Over the past 30 days, multiple analysts have rated the company as a Buy.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Industry at a Glance
Industry Ranking
154 / 280
Overall Ranking
361 / 4751
Industry
Healthcare Services & Equipment
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analysts' Target
Based on
5
analysts
Buy
Current Rating
35.157
Target Price
-5.57%
Upside Space
Disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. Its segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip and knee Implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that help surgeons, and trauma products used to stabilize severe fractures and correct hard tissue deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 84.75.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 79.37%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 79.37%.
Overvalued
The company’s latest PE is 33.32, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 34.86M shares, decreasing 25.88% quarter-over-quarter.
Held by Brandes Investmen
Star Investor Brandes Investmen holds 1.60M shares of this stock.
Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. Its segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip and knee Implants used to replace diseased, damaged or worn joints, robotics-assisted and digital enabling technologies and services that help surgeons, and trauma products used to stabilize severe fractures and correct hard tissue deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.